TIDMAZN
RNS Number : 0007F
AstraZeneca PLC
17 February 2015
ASTRAZENECA ANNOUNCES NON-EXECUTIVE BOARD CHANGES
17 February 2015
AstraZeneca today announced that Dr Cornelia (Cori) Bargmann
will be proposed to shareholders for election as a Non-Executive
Director at the Company's Annual General Meeting (AGM) on 24 April
2015. On election, the Board also proposes appointing Dr Bargmann
to AstraZeneca's Science Committee.
Cori is the Torsten N. Wiesel Professor and head of the Lulu and
Anthony Wang Laboratory of Neural Circuits and Behavior at The
Rockefeller University, New York, and a Howard Hughes Medical
Institute investigator.
John Varley, senior independent Non-Executive Director and Dame
Nancy Rothwell, Non-Executive Director, both intend to retire from
the Board at the close of the AGM on 24 April 2015, each having
served as a Board member for nine years. John is currently Chairman
of the Remuneration Committee and a member of the Nomination and
Governance Committee. Dame Nancy Rothwell is currently Chairman of
the Science Committee, and a member of the Remuneration Committee
and the Nomination and Governance Committee.
As a result of the retirement of John Varley and Dame Nancy
Rothwell, the following Board Committee changes will take place
with effect from the close of the AstraZeneca 2015 AGM:
-- Rudy Markham will become senior independent Non-Executive Director.
-- Graham Chipchase will become Chairman of the Remuneration
Committee and a member of the Nomination and Governance
Committee.
-- Bruce Burlington will become Chairman of the Science
Committee and a member of the Nomination and Governance
Committee.
-- Geneviève Berger will oversee sustainability matters on behalf of the Board.
In addition, Shriti Vadera will become a member of the
Remuneration Committee with immediate effect.
Leif Johansson, AstraZeneca Chairman, said: "John Varley and
Dame Nancy Rothwell have been committed and hard-working Board
members, serving the Company and its shareholders for the best part
of a decade. I would like to pay tribute to their experience,
wisdom, common sense and collegiality, as well as their leadership
of the Remuneration Committee and the Science Committee
respectively. I speak for all of my colleagues on the Board in
saying that we will miss them and their contribution to our work;
they go with our very best wishes for their future endeavours."
"Their retirement has provided us with an opportunity to propose
the appointment of new Board members. We welcomed Ann Cairns last
year and are delighted that Cori Bargmann has agreed to join the
Board in April. Cori will bring a wealth of experience in
scientific research, fitting the needs of AstraZeneca's Board very
well."
All other current Directors will be presenting themselves for
re-election at the AGM, in accordance with AstraZeneca's normal
practice.
In making the proposals and Board Committee appointments
described above, the Board considered and satisfied itself as to
the availability and time commitment of the Directors
concerned.
In relation to the proposed election of Cori Bargmann as a
Non-Executive Director, there are no directorships to disclose
under paragraph (1) and no disclosure obligations arise under
paragraphs (2) to (6) of LR 9.6.13 R of the UK Listing Authority's
Listing Rules.
-ENDS-
NOTES TO EDITORS
Dr Cori Bargmann - biographical details
Dr Cori Bargmann is the Torsten N. Wiesel Professor and head of
the Lulu and Anthony Wang Laboratory of Neural Circuits and
Behavior at The Rockefeller University, New York. She has been a
Howard Hughes Medical Institute investigator since 1995. She is a
neurobiologist who studies the relationships between genes, neural
circuits and behaviour using C. elegans, a tiny roundworm, as the
model for her work. Many of the genes and neural pathways in C.
elegans are similar to those of mammals and their study provides an
insight into the development and functioning of neural
circuits.
Cori holds a degree in biochemistry from the University of
Georgia and a Ph.D. from the Massachusetts Institute of Technology,
where she studied oncogenes with Robert Weinberg. She pursued a
postdoctoral fellowship with H. Robert Horvitz at MIT until 1991,
when she accepted a faculty position in the Department of Anatomy
at the University of California, San Francisco, spending 13 years
there, latterly as Vice-Chair of the department. She took up her
current position at The Rockefeller University in 2004.
Cori is the recipient of the 2015 Benjamin Franklin Medal in
Life Science, one of nine individuals who will be presented with
awards by The Franklin Institute, Philadelphia this year. The award
is for her contributions to neurobiology that have led to major
discoveries elucidating the relationship between genes, neurons,
neural circuits and behaviour.
Membership of AstraZeneca Board Committees, with effect from the
close of the AGM on 24 April 2015
Audit Committee
Rudy Markham (Chairman of the Committee)
Bruce Burlington
Ann Cairns
Jean-Philippe Courtois
Shriti Vadera
Remuneration Committee
Graham Chipchase (Chairman of the Committee)
Leif Johansson
Rudy Markham
Shriti Vadera
Nomination and Governance Committee
Leif Johansson (Chairman of the Committee)
Bruce Burlington
Graham Chipchase
Rudy Markham
Science Committee
Bruce Burlington (Chairman of the Committee)
Cori Bargmann
Geneviève Berger
Marcus Wallenberg
About AstraZeneca
AstraZeneca is a global, innovation-driven biopharmaceutical
business that focuses on the discovery, development and
commercialisation of prescription medicines, primarily for the
treatment of cardiovascular, metabolic, respiratory, inflammation,
autoimmune, oncology, infection and neuroscience diseases.
AstraZeneca operates in over 100 countries and its innovative
medicines are used by millions of patients worldwide. For more
information please visit: www.astrazeneca.com
CONTACTS
Media Enquiries
Esra Erkal-Paler +44 20 7604 8030 (UK/Global)
Vanessa Rhodes +44 20 7604 8037 (UK/Global)
Ayesha Bharmal +44 20 7604 8034 (UK/Global)
Jacob Lund +46 8 553 260 20 (Sweden)
Michele Meixell + 1 302 885 6351 (US)
Investor Enquiries
Thomas Kudsk Larsen +44 20 7604 8199 mob: +44 7818 524185
Karl Hård +44 20 7604 8123 mob: +44 7789 654364
Eugenia Litz +44 20 7604 8233 mob: +44 7884 735627
Craig Marks +44 20 7604 8591 mob: +44 7881 615764
Christer Gruvris +44 20 7604 8126 mob: +44 7827 836825
This information is provided by RNS
The company news service from the London Stock Exchange
END
BOASFLFSMFISEIE
Astrazeneca (LSE:AZN)
Historical Stock Chart
From Apr 2024 to May 2024
Astrazeneca (LSE:AZN)
Historical Stock Chart
From May 2023 to May 2024